In Vitro and In Vivo Gene Therapy Vector Evolution via Multispecies Interbreeding and Retargeting of Adeno-Associated Viruses
Open accessThe DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Abstract
Adeno-associated virus (AAV) serotypes differ broadly in transduction efficacies and tissue tropisms and thus hold enormous potential as vectors for human gene therapy. In reality, however, their use in patients is restricted by prevalent anti-AAV immunity or by their inadequate performance in specific targets, exemplified by the AAV type 2 (AAV-2) prototype in the liver. Here, we attempted to merge desirable qualities of multiple natural AAV isolates by an adapted DNA family shuffling technology to create a complex library of hybrid capsids from eight different wild-type viruses. Selection on primary or transformed human hepatocytes yielded pools of hybrids from five of the starting serotypes: 2, 4, 5, 8, and 9. More stringent selection with pooled human antisera (intravenous immunoglobulin [IVIG]) then led to the selection of a single type 2/type 8/type 9 chimera, AAV-DJ, distinguished from its closest natural relative (AAV-2) by 60 capsid amino acids. Recombinant AAV-DJ vectors outperformed eight standard AAV serotypes in culture and greatly surpassed AAV-2 in livers of naïve and IVIG-immunized mice. A heparin binding domain in AAV-DJ was found to limit biodistribution to the liver (and a few other tissues) and to affect vector dose response and antibody neutralization. Moreover, we report the first successful in vivo biopanning of AAV capsids by using a new AAV-DJ-derived viral peptide display library. Two peptides enriched after serial passaging in mouse lungs mediated the retargeting of AAV-DJ vectors to distinct alveolar cells. Our study validates DNA family shuffling and viral peptide display as two powerful and compatible approaches to the molecular evolution of novel AAV vectors for human gene therapy applications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, directed evolution has been applied to generate AAV variants capable of evading neutralizing antibodies in vitro and in vivo.68–72”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [72]
In the citing paper
“New AAV variants created through directed evolution withstood up to 35-fold higher in vitro concentrations of pooled human antibodies than AAV2.”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [72]
In the citing paper
“These antibody neutralization properties also led to enhanced transduction in vivo, where AAV variants were capable of significantly higher transduction in the liver, heart and muscle than AAV2 in mice passively immunized with human antibodies.”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [72]
In the citing paper
“Similarly, AAV-DJ can only transduce a confined region but with higher efficiency than AAV2, suggesting an ideal vector for desired expression within a small area [63].”
From Designing and optimizing AAV-mediated gene therapy for neurodegenerative diseases: from bench to bedside (2024) · cites this paper as [63]
In the citing paper
“Compared with natural variants, the engineered AAV-DJ variant, consisting of residues from AAV2, AAV8, and AAV9 variants, has been shown to transduce hepatocytes in the presence of human intravenous IgG [194, 195].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [195]
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationRapid evolution of a protein in vitro by DNA shuffling
Stemmer, W. P. C. (1994) · Nature · doi:10.1038/370389a0 · Cited by 1,932
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A. (2006) · Nature · doi:10.1038/nature04791 · Cited by 1,677
Self-citationNovel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520
Self-citationSummerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,406
Stemmer, W. P. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.22.10747 · Cited by 1,284
Improved Green Fluorescent Protein by Molecular Evolution Using DNA Shuffling
Crameri, A., Whitehorn, E. A., Tate, E., & Stemmer, W. P. C. (1996) · Nature Biotechnology · doi:10.1038/nbt0396-315 · Cited by 1,187
Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070
Kay, M. A., Manno, C. S., Ragni, M. V., Larson, P. J., Couto, L. B., McClelland, A., Glader, B., Chew, A. J., J Tai, S., Herzog, R. W., et al. (2000) · Nature Genetics · doi:10.1038/73464 · Cited by 1,022
Self-citationAdeno-associated Virus Serotypes: Vector Toolkit for Human Gene Therapy
Wu, Z., Asokan, A., & Samulski, R. J. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.05.009 · Cited by 922
DNA shuffling of a family of genes from diverse species accelerates directed evolution
Crameri, A., Raillard, S.-A., Bermudez, E., & Stemmer, W. P. C. (1998) · Nature · doi:10.1038/34663 · Cited by 825
Inagaki, K., Fuess, S., Storm, T. A., Gibson, G. A., Mctiernan, C. F., Kay, M. A., & Nakai, H. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.014 · Cited by 610
Self-citationA "humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells
Zolotukhin, S., Potter, M., Hauswirth, W. W., Guy, J., & Muzyczka, N. (1996) · Journal of Virology · doi:10.1128/jvi.70.7.4646-4654.1996 · Cited by 609
Snyder, R. O., Miao, C. H., Patijn, G. A., Spratt, S. K., Danos, O., Nagy, D., Gown, A. M., Winther, B., Meuse, L., Cohen, L. K., et al. (1997) · Nature Genetics · doi:10.1038/ng0797-270 · Cited by 579
Self-citationDirected evolution of adeno-associated virus yields enhanced gene delivery vectors
Maheshri, N., Koerber, J. T., Kaspar, B. K., & Schaffer, D. V. (2006) · Nature Biotechnology · doi:10.1038/nbt1182 · Cited by 538
A Viral Phospholipase A2 Is Required for Parvovirus Infectivity
Zádori, Z., Szelei, J., Lacoste, M.-C., Li, Y., Gariépy, S., Raymond, P., Allaire, M., Nabi, I. R., & Tijssen, P. (2001) · Developmental Cell · doi:10.1016/s1534-5807(01)00031-4 · Cited by 518
Akache, B., Grimm, D., Pandey, K., Yant, S. R., Xu, H., & Kay, M. A. (2006) · Journal of Virology · doi:10.1128/jvi.00878-06 · Cited by 430
Self-citationNathwani, A. C., Gray, J. T., Ng, C. Y. C., Zhou, J., Spence, Y., Waddington, S. N., Tuddenham, E. G. D., Kemball-Cook, G., McIntosh, J., Boon-Spijker, M., et al. (2006) · Blood · doi:10.1182/blood-2005-10-4035 · Cited by 421
Müller, O. J., Kaul, F., Weitzman, M. D., Pasqualini, R., Arap, W., Kleinschmidt, J. A., & Trepel, M. (2003) · Nature Biotechnology · doi:10.1038/nbt856 · Cited by 410 · cited 1×
“bone used here (it had to be mutated in the original cloning strategy [50]; see also”
BackgroundGenetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2
Girod, A., Ried, M., Wobus, C., Lahm, H., Leike, K., Kleinschmidt, J., Deléage, G., & Hallek, M. (1999) · Nature Medicine · doi:10.1038/12491 · Cited by 405
Wu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., & Muzyczka, N. (2000) · Journal of Virology · doi:10.1128/jvi.74.18.8635-8647.2000 · Cited by 390 · cited 3×
“Noteworthy here are approaches to fuse targeting ligands to the N termini of AAV capsid proteins (ideally, VP2 [45, 83]), or more powerful, to insert short peptides (up to 14 amino acids [21], typically 7) into exposed regions of the assembled virion.”
BackgroundIdentification of a heparin-binding motif on adeno-associated virus type 2 capsids
Kern, A., Schmidt, K., Leder, C., Müller, O. J., Wobus, C. E., Bettinger, K., Von der Lieth, C. W., King, J. A., & Kleinschmidt, J. A. (2003) · Journal of Virology · doi:10.1128/jvi.77.20.11072-11081.2003 · Cited by 380 · cited 1×
“We also indirectly confirmed key residues constituting the HBD (previously identified via mutagenesis; R484-487-585-588 and K532 [37, 56]), based on conservation in all our selected clones and the critical role of the HBD in vitro.”
BackgroundOpie, S. R., Warrington, Agbandje-McKenna, M., Zolotukhin, S., & Muzyczka, N. (2003) · Journal of Virology · doi:10.1128/jvi.77.12.6995-7006.2003 · Cited by 364 · cited 1×
“We also indirectly confirmed key residues constituting the HBD (previously identified via mutagenesis; R484-487-585-588 and K532 [37, 56]), based on conservation in all our selected clones and the critical role of the HBD in vitro.”
BackgroundThomas, C. E., Storm, T. A., Huang, Z., & Kay, M. A. (2004) · Journal of Virology · doi:10.1128/jvi.78.6.3110-3122.2004 · Cited by 358
Self-citationGrimm, D., & Kay, M. (2003) · Current Gene Therapy · doi:10.2174/1566523034578285 · Cited by 350
Self-citationUnrestricted Hepatocyte Transduction with Adeno-Associated Virus Serotype 8 Vectors in Mice
Nakai, H., Fuess, S., Storm, T. A., Muramatsu, S.-I., Nara, Y., & Kay, M. A. (2005) · Journal of Virology · doi:10.1128/jvi.79.1.214-224.2005 · Cited by 327
Self-citationImmune Responses to AAV in Clinical Trials
Mingozzi, F., & A. High, K. (2011) · Current Gene Therapy · doi:10.2174/156652311796150354 · Cited by 324
Adeno-associated viruses undergo substantial evolution in primates during natural infections
Gao, G., Alvira, M. R., Somanathan, S., Lu, Y., Vandenberghe, L. H., Rux, J. J., Calcedo, R., Sanmiguel, J., Abbas, Z., & Wilson, J. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0937739100 · Cited by 323
Sonntag, F., Bleker, S., Leuchs, B., Fischer, R., & Kleinschmidt, J. A. (2006) · Journal of Virology · doi:10.1128/jvi.01056-06 · Cited by 280
Directed evolution of proteins by exon shuffling
Kolkman, J. A., & Stemmer, W. P. C. (2001) · Nature Biotechnology · doi:10.1038/88084 · Cited by 273
Wobus, C. E., Hügle-Dörr, B., Girod, A., Petersen, G., Hallek, M., & Kleinschmidt, J. A. (2000) · Journal of Virology · doi:10.1128/jvi.74.19.9281-9293.2000 · Cited by 273
Scallan, C. D., Jiang, H., Liu, T., Patarroyo-White, S., Sommer, J. M., Zhou, S., Couto, L. B., & Pierce, G. F. (2006) · Blood · doi:10.1182/blood-2005-08-3229 · Cited by 271
Incorporation of Tumor-Targeting Peptides into Recombinant Adeno-associated Virus Capsids
Grifman, M., Trepel, M., Speece, P., Gilbert, L. B., Arap, W., Pasqualini, R., & Weitzman, M. D. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0345 · Cited by 241
Immune Responses to AAV in Clinical Trials
Mingozzi, F., & High, K. (2007) · Current Gene Therapy · doi:10.2174/156652307782151425 · Cited by 238
Wu, Z., Asokan, A., Grieger, J. C., Govindasamy, L., Agbandje-McKenna, M., & Samulski, R. J. (2006) · Journal of Virology · doi:10.1128/jvi.01288-06 · Cited by 237
Bartlett, J. S., Kleinschmidt, J., Boucher, R. C., & Samulski, R. J. (1999) · Nature Biotechnology · doi:10.1038/6185 · Cited by 230
In vitro selection of viral vectors with modified tropism: the adeno-associated virus display
Perabo, L., Büning, H., Kofler, D. M., Ried, M. U., Girod, A., Wendtner, C. M., Enssle, J., & Hallek, M. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00123-0 · Cited by 229
Efficient and Selective AAV2-Mediated Gene Transfer Directed to Human Vascular Endothelial Cells
Nicklin, S. A., Buening, H., Dishart, K. L., de Alwis, M., Girod, A., Hacker, U., Thrasher, A. J., Ali, R. R., Hallek, M., & Baker, A. H. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0424 · Cited by 219
Subcellular compartmentalization of adeno-associated virus type 2 assembly
Wistuba, A., Kern, A., Weger, S., Grimm, D., & Kleinschmidt, J. A. (1997) · Journal of Virology · doi:10.1128/jvi.71.2.1341-1352.1997 · Cited by 219
Self-citationHeparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid
Vandenberghe, L. H., Wang, L., Somanathan, S., Zhi, Y., Figueredo, J., Calcedo, R., Sanmiguel, J., Desai, R. A., Chen, C. S., Johnston, J., et al. (2006) · Nature Medicine · doi:10.1038/nm1445 · Cited by 208
Self-citationPreclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy
Grimm, D., Zhou, S., Nakai, H., Thomas, C. E., Storm, T. A., Fuess, S., Matsushita, T., Allen, J., Surosky, R., Lochrie, M., et al. (2003) · Blood · doi:10.1182/blood-2003-02-0495 · Cited by 208
Self-citationLochrie, M. A., Tatsuno, G. P., Christie, B., McDonnell, J. W., Zhou, S., Surosky, R., Pierce, G. F., & Colosi, P. (2006) · Journal of Virology · doi:10.1128/jvi.80.2.821-834.2006 · Cited by 201 · cited 1×
“Hence, the sum of all previous attempts at directed AAV evolution, including four libraries and over 370 mutants from multiple groups (also counting site-directed mutagenesis strategies [42]), did not change more than 1% of capsid residues, at best.”
BackgroundBleker, S., Sonntag, F., & Kleinschmidt, J. A. (2005) · Journal of Virology · doi:10.1128/jvi.79.4.2528-2540.2005 · Cited by 200
Kronenberg, S., Böttcher, B., von der Lieth, C. W., Bleker, S., & Kleinschmidt, J. A. (2005) · Journal of Virology · doi:10.1128/jvi.79.9.5296-5303.2005 · Cited by 198
Targeted Gene Delivery to Vascular Tissue In Vivo by Tropism-Modified Adeno-Associated Virus Vectors
White, S. J., Nicklin, S. A., Büning, H., Brosnan, M. J., Leike, K., Papadakis, E. D., Hallek, M., & Baker, A. H. (2004) · Circulation · doi:10.1161/01.cir.0000109697.68832.5d · Cited by 193
AAV hybrid serotypes: improved vectors for gene delivery
Choi, V., McCarty, D., & Samulski, R. (2005) · Current Gene Therapy · doi:10.2174/1566523054064968 · Cited by 191
Asokan, A., Hamra, J. B., Govindasamy, L., Agbandje-McKenna, M., & Samulski, R. J. (2006) · Journal of Virology · doi:10.1128/jvi.00843-06 · Cited by 183
Wang, L., Calcedo, R., Nichols, T. C., Bellinger, D. A., Dillow, A., Verma, I. M., & Wilson, J. M. (2005) · Blood · doi:10.1182/blood-2004-10-3867 · Cited by 173
Self-citationRabinowitz, J. E., Bowles, D. E., Faust, S. M., Ledford, J. G., Cunningham, S. E., & Samulski, R. J. (2004) · Journal of Virology · doi:10.1128/jvi.78.9.4421-4432.2004 · Cited by 171
Biology of AAV Serotype Vectors in Liver-Directed Gene Transfer to Nonhuman Primates
Gao, G., Lu, Y., Calcedo, R., Grant, R. L., Bell, P., Wang, L., Figueredo, J., Lock, M., & Wilson, J. M. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.08.017 · Cited by 170
Self-citationShi, W., & Bartlett, J. S. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00042-x · Cited by 164
Kwon, I., & Schaffer, D. V. (2008) · Pharmaceutical Research · doi:10.1007/s11095-007-9431-0 · Cited by 164
Generation and characterization of chimeric recombinant AAV vectors
Hauck, B., Chen, L., & Xiao, W. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00012-1 · Cited by 160
Lux, K., Goerlitz, N., Schlemminger, S., Perabo, L., Goldnau, D., Endell, J., Leike, K., Kofler, D. M., Finke, S., Hallek, M., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.18.11776-11787.2005 · Cited by 152 · cited 3×
“Noteworthy here are approaches to fuse targeting ligands to the N termini of AAV capsid proteins (ideally, VP2 [45, 83]), or more powerful, to insert short peptides (up to 14 amino acids [21], typically 7) into exposed regions of the assembled virion.”
BackgroundWistuba, A., Weger, S., Kern, A., & Kleinschmidt, J. A. (1995) · Journal of Virology · doi:10.1128/jvi.69.9.5311-5319.1995 · Cited by 147
Receptor targeting of adeno-associated virus vectors
Büning, H., Ried, M. U., Perabò, L., Gerner, F., Huttner, N. A., Enssle, J., & Hallek, M. J. (2003) · Gene Therapy · doi:10.1038/sj.gt.3301976 · Cited by 144
Lukashov, V. V., & Goudsmit, J. (2001) · Journal of Virology · doi:10.1128/jvi.75.6.2729-2740.2001 · Cited by 141
Evolution of a cytokine using DNA family shuffling
Chang, C.-C. J., Chen, T. T., Cox, B. W., Dawes, G. N., Stemmer, W. P. C., Punnonen, J., & Patten, P. A. (1999) · Nature Biotechnology · doi:10.1038/11737 · Cited by 140
Combinatorial engineering of a gene therapy vector: directed evolution of adeno‐associated virus
Perabo, L., Endell, J., King, S., Lux, K., Goldnau, D., Hallek, M., & Büning, H. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.849 · Cited by 136
Perabo, L., Goldnau, D., White, K., Endell, J., Boucas, J., Humme, S., Work, L. M., Janicki, H., Hallek, M., Baker, A. H., et al. (2006) · Journal of Virology · doi:10.1128/jvi.00076-06 · Cited by 134
Directed evolution of thymidine kinase for AZT phosphorylation using DNA family shuffling
Christians, F. C., Scapozza, L., Crameri, A., Folkers, G., & Stemmer, W. P. C. (1999) · Nature Biotechnology · doi:10.1038/7003 · Cited by 125
Vascular bed-targeted in vivo gene delivery using tropism-modified adeno-associated viruses
Work, L. M., Büning, H., Hunt, E., Nicklin, S. A., Denby, L., Britton, N., Leike, K., Odenthal, M., Drebber, U., Hallek, M., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.11.013 · Cited by 125
Characterization of Tissue Tropism Determinants of Adeno-Associated Virus Type 1
Hauck, B., & Xiao, W. (2003) · Journal of Virology · doi:10.1128/jvi.77.4.2768-2774.2003 · Cited by 124
Huttner, N. A., Girod, A., Perabo, L., Edbauer, D., Kleinschmidt, J. A., Büning, H., & Hallek, M. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302123 · Cited by 124
Production methods for gene transfer vectors based on adeno-associated virus serotypes
Grimm, D. (2002) · Methods · doi:10.1016/s1046-2023(02)00219-0 · Cited by 121
Self-citationLoiler, S., Conlon, T. J., Song, S., Tang, Q., Warrington, K. H., Agarwal, A., Kapturczak, M., Li, C., Ricordi, C., Atkinson, M. A., et al. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302046 · Cited by 119
Grimm, D., Pandey, K., Nakai, H., Storm, T. A., & Kay, M. A. (2006) · Journal of Virology · doi:10.1128/jvi.80.1.426-439.2006 · Cited by 118
Self-citationDevelopment of Efficient Viral Vectors Selective for Vascular Smooth Muscle Cells
Work, L. M., Nicklin, S. A., Brain, N. J. R., Dishart, K. L., Von Seggern, D. J., Hallek, M., Büning, H., & Baker, A. H. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2003.11.006 · Cited by 115
Soong, N.-W., Nomura, L. E., Pekrun, K., Reed, M., Sheppard, L., Dawes, G. N., & Stemmer, W. P. C. (2000) · Nature Genetics · doi:10.1038/78132 · Cited by 101
Nakai, H., Thomas, C. E., Storm, T. A., Fuess, S., Powell, S., Wright, J. F., & Kay, M. A. (2002) · Journal of Virology · doi:10.1128/jvi.76.22.11343-11349.2002 · Cited by 99
Self-citationMolecular Characterization of Adeno-Associated Viruses Infecting Children
Chen, C.-L., Jensen, R. L., Schnepp, B. C., Connell, M. J., Shell, R., Sferra, T. J., Bartlett, J. S., Clark, K. R., & Johnson, P. R. (2005) · Journal of Virology · doi:10.1128/jvi.79.23.14781-14792.2005 · Cited by 99
Breeding of retroviruses by DNA shuffling for improved stability and processing yields
Powell, S. K., Kaloss, M., Pinkstaff, A., McKee, R. C., Burimski, I., Pensiero, M., Otto, E., Stemmer, W. P. C., & Soong, N.-W. (2000) · Nature Biotechnology · doi:10.1038/82391 · Cited by 91
Adeno-Associated Virus Vectors for Short Hairpin RNA Expression
Grimm, D., Pandey, K., & Kay, M. A. (2005) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(04)92023-x · Cited by 90
Self-citationTherapeutic short hairpin RNA expression in the liver: viral targets and vectors
Grimm, D., & Kay, M. A. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302727 · Cited by 86
Self-citationAkache, B., Grimm, D., Shen, X., Fuess, S., Yant, S. R., Glazer, D. S., Park, J., & Kay, M. A. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300053 · Cited by 85
Self-citationCustom Adeno-Associated Virus Capsids: The Next Generation of Recombinant Vectors with Novel Tropism
Muzyczka, N., & Warrington, K. H. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.408 · Cited by 80
Arnold, G. S., Sasser, A. K., Stachler, M. D., & Bartlett, J. S. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.02.014 · Cited by 79 · cited 1×
“, bispecific antibodies [6] or avidin-coupled ligands [4]) are allowed to react with the viral surface (biotinylated in the case of avidin [4]), as well as a cellular receptor, forming a conjugate ideally able to retarget the capsid to a refractory cell type.”
BackgroundGao, G.-P., Lu, Y., Sun, X., Johnston, J., Calcedo, R., Grant, R., & Wilson, J. M. (2006) · Journal of Virology · doi:10.1128/jvi.00526-06 · Cited by 78
Michelfelder, S., Lee, M., deLima-Hahn, E., Wilmes, T., Kaul, F., Müller, O. J., Kleinschmidt, J. A., & Trepel, M. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2007.07.018 · Cited by 72
Arbetman, A. E., Lochrie, M., Zhou, S., Wellman, J., Scallan, C., Doroudchi, M. M., Randlev, B., Patarroyo-White, S., Liu, T., Smith, P., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.24.15238-15245.2005 · Cited by 71 · cited 1×
“The reverse primer was 5 AAAC GAATTCGCCCTTCGCAGAGACCAAAGTTCAACTGAAACGAA TCAACCGG TTTATT GATTAACAGGCAA N23 3 (the nucleotides restoring the PmeI site are underlined, the polyadenylation signal is shown in bold, and N23 denotes the last [ 3 ] 23 nt of the shuffled capsid genes, TTACAGATTAC GGGTGAGGTAAC for AAV-DJ [3-to-…”
MethodIsolation of targeted AAV2 vectors from novel virus display libraries
Waterkamp, D. A., Müller, O. J., Ying, Y., Trepel, M., & Kleinschmidt, J. A. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.967 · Cited by 69
Bowles, D. E., Rabinowitz, J. E., & Samulski, R. J. (2003) · Journal of Virology · doi:10.1128/jvi.77.1.423-432.2003 · Cited by 67
Koerber, J. T., Jang, J.-H., Yu, J. H., Kane, R. S., & Schaffer, D. V. (2007) · Human Gene Therapy · doi:10.1089/hum.2006.139 · Cited by 64
Characterization of the Relationship of AAV Capsid Domain Swapping to Liver Transduction Efficiency
Shen, X., Storm, T., & Kay, M. A. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300293 · Cited by 59
Self-citationImmune Responses to AAV Capsid: Are Mice Not Humans After All?
Herzog, R. W. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300123 · Cited by 56
Zhong, L., Li, W., Li, Y., Zhao, W., Wu, J., Li, B., Maina, N., Bischof, D., Qing, K., Weigel-Kelley, K. A., et al. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.321 · Cited by 32
Pekrun, K., Shibata, R., Igarashi, T., Reed, M., Sheppard, L., Patten, P. A., Stemmer, W. P. C., Martin, M. A., & Soong, N.-W. (2002) · Journal of Virology · doi:10.1128/jvi.76.6.2924-2935.2002 · Cited by 26
Library Selection and Directed Evolution Approaches to Engineering Targeted Viral Vectors
Jang, J., Lim, K., & Schaffer, D. V. (2007) · Biotechnology and Bioengineering · doi:10.1002/bit.21541 · Cited by 26
Shi, W., Hemminki, A., & Bartlett, J. S. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.06.020 · Cited by 15
Cited by
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Viral vector platforms within the gene therapy landscape
Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L., & Gao, G. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00487-6 · Cited by 1,404
Engineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175
Social reward requires coordinated activity of nucleus accumbens oxytocin and serotonin
Dölen, G., Darvishzadeh, A., Huang, K. W., & Malenka, R. C. (2013) · Nature · doi:10.1038/nature12518 · Cited by 1,161
Young blood reverses age-related impairments in cognitive function and synaptic plasticity in mice
Villeda, S. A., Plambeck, K. E., Middeldorp, J., Castellano, J. M., Mosher, K. I., Luo, J., Smith, L. K., Bieri, G., Lin, K., Berdnik, D., et al. (2014) · Nature Medicine · doi:10.1038/nm.3569 · Cited by 1,081
Metadata
- Authors
- Grimm, D., Lee, J. S., Wang, L., Desai, T., Akache, B., Storm, T. A., & Kay, M. A.
- Affiliations
- Stanford Medicine (US)
- Pediatrics and Genetics (US)
- Stanford University (US)
- Corresponding author
- Kay, Mark A.
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2008-06-15
- Volume
- 82
- Issue
- 12
- Pages
- 5887-5911
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- PMC
- PMC2395137
- OpenAlex
- W2147193337
- Cited by
- 696
- References
- 89
- Citations by year
- 2026: 29 · 2025: 53 · 2024: 67 · 2023: 50 · 2022: 60 · 2021: 56 · 2020: 53 · 2019: 54 · 2018: 36 · 2017: 40 · 2016: 33 · 2015: 33 · 2014: 34 · 2013: 19 · 2012: 16
- FWCI
- 11.40
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Journal of Virology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (HL64274, R01HL064274)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- adeno-associated virus, AAV serotypes, gene therapy vectors, AAV2
- MeSH terms
- Dependovirus, Animals, Female, Genetic Engineering, Genetic Vectors, Humans, Mice, Inbred C57BL, Mice, Inbred Strains, Genetic Therapy, Gene Transfer Techniques, Evolution, Molecular, DNA Shuffling, Mice, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.